Quick Answer
OnKure Therapeutics, Inc. reported Total Assets of $62.12 million for the year ending 2025.
- OnKure Therapeutics, Inc. showed a decrease of -45.9% in Total Assets from 2024 to 2025.
- This data is from OnKure Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $95.32 million | Q2 2021: $171.30 million | Q3 2021: $162.94 million | Q1 2022: $144.41 million | Q2 2022: $133.61 million | Q3 2022: $122.50 million | Q1 2023: $98.87 million | Q2 2023: $148.04 million | Q3 2023: $130.39 million | Q1 2024: $84.64 million | Q2 2024: $78.72 million | Q3 2024: $77.65 million | Q1 2025: $99.88 million | Q2 2025: $86.07 million | Q3 2025: $72.84 million.
- Over the full 6 years of available data (2020 to 2025), OnKure Therapeutics, Inc.'s Total Assets has grown by 12.5%.
- Historical annual values: Fiscal year 2025: $62.12 million | Fiscal year 2024: $114.91 million | Fiscal year 2023: $35.73 million | Fiscal year 2022: $108.18 million | Fiscal year 2021: $154.02 million | Fiscal year 2020: $55.22 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: